… Since human papillomavirus (HPV) vaccine was first introduced for females in the United
States in 2006, vaccination policy has evolved as additional HPV vaccines were licensed and …

… Multivalent human papillomavirus vaccines. Some countries have implemented or have
plans to commence the use of 9vHPV vaccines to offer protection against the additional five next …

Key Clinical Points Human Papillomavirus Vaccination Human papillomavirus (HPV) is a
common sexually transmitted virus. Most HPV infections clear or become undetectable within 1 …

… effect of a male vaccination program on female human papillomavirus (HPV) infection rates
and cervical cancer incidence, we needed to directly model the effect of vaccination on HPV …

We present a transmission dynamic model that can assess the epidemiologic consequences
and cost-effectiveness of alternative strategies of administering a prophylactic quadrivalent (…

… The licensed vaccines are safe and highly effective against the most common human
papillomavirus (HPV) types found in cervical and other anogenital cancers and are likely to prevent …

… beliefs about human papillomavirus vaccines and fewer practical barriers to vaccination are
… A quadrivalent human papillomavirus (HPV) vaccine was licensed by the US Food and Drug …

… The availability of prophylactic human papillomavirus (HPV) vaccines has provided …
vaccines have each been licensed in over 100 countries. By the beginning of 2012, HPV vaccine …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

OBJECTIVE: The goal was to describe factors associated with human papillomavirus (HPV)
vaccination series initiation (≥1 dose) and completion (≥3 doses) and parents' intent to …